Donor-specific antibodies (DSAs) are a barrier to improved long-term outcomes after kidney transplantation. Costimulation blockade with CTLA4-Ig has shown promise as a potential therapeutic strategy to control DSAs. T follicular helper (Tfh) cells, a subset of CD4 + T cells required for optimal antibody production, are reliant on the CD28 costimulatory pathway. We have previously shown that selective CD28 blockade leads to superior allograft survival through improved control of CD8 + T cells relative to CTLA4-Ig, but the impact of CD28-specific blockade on CD4 + Tfh cells is unknown. Thus, we identified and characterized donor-reactive Tfh cells in a murine skin transplant model and then used this model to evaluate the impact of selective CD28 blockade with an anti-CD28 domain antibody (dAb) on the donor-specific Tfh cellmediated immune response. We observed that the anti-CD28 dAb led to superior inhibition of donorreactive CXCR5 + PD-1 high Tfh cells, CD95 + GL7 + germinal center B cells and DSA formation compared with CTLA4-Ig. Interestingly, donor-reactive Tfh cells differentially upregulated CTLA4 expression, suggesting an important role for CTLA4 in mediating the superior inhibition observed with the anti-CD28 dAb. Therefore, selective CD28 blockade as a novel approach to control Tfh cell responses and prevent DSA after kidney transplantation warrants further study.
Introduction
Anti-HLA donor-specific antibodies (DSAs) are an increasingly recognized barrier to improved long-term outcomes after kidney transplantation (1, 2) . Both preexisting and de novo DSAs portend inferior kidney transplantation outcomes (3) (4) (5) (6) . Currently, 14% of the patients on the renal transplant waitlist are highly sensitized (cPRA > 80%) (7) , and de novo DSA rates under calcineurin inhibitor (CNI)-based immunosuppression are estimated to be 20% (6, 8) . Despite the large burden of anti-HLA antibodies, existing therapeutic options to combat either preformed or de novo alloantibodies are suboptimal and mostly unproved with limited efficacy (9) . A better understanding of the mechanistic underpinnings of DSA formation and persistence is needed to guide the development of novel strategies to control DSAs and improve outcomes.
CTLA4 (cytotoxic T-lymphocyte associated protein 4)-Ig in the form of belatacept, a first-in-class costimulation blocker that was approved by the US Food and Drug Administration in 2011 for maintenance immunosuppression after kidney transplantation, offers a new therapeutic option to improve long-term outcomes (10) . Seven-year results from a phase 3 study showed that patient and graft survival rates were significantly higher with belatacept than with a CNI-based regimen. The reasons underlying improved outcomes with belatacept are likely multifactorial and include less nephrotoxicity and metabolic toxicity (11, 12) , but improved prevention of de novo DSAs may be a contributing factor (2, 5) . Lower rates of DSAs were observed with belatacept compared with CNIs (10, 13) , but the ultimate effect of belatacept on DSAs is not known, nor is the effect on highly sensitized recipients with or without preexisting DSAs (14) . Moreover, preliminary data from an ongoing clinical trial designed to evaluate the ability of belatacept monotherapy to prevent DSA formation in kidney transplant recipients with failed allografts indicate that belatacept alone may not be sufficient to completely prevent DSAs in this setting (I. R. Badell, unpublished data). Therefore, optimization of current costimulation blockade (i.e. CTLA4-Ig) as a tool to treat anti-HLA antibodies remains an important goal.
Long-standing experimental evidence suggests that costimulation blockade of the CD28 pathway with CTLA4-Ig in mice and primates is an effective means of preventing alloantibody formation (15, 16) , but the underlying mechanisms responsible for this observation are not known. Tfh cells are a newly defined CD4 + T cell subset required for mature, high-affinity antibody responses through the formation of germinal centers (GCs) and provision of optimal B cell help (17) . Tfh cells are distinguishable by their unique expression of CXCR5, high levels of programmed call death protein 1 (PD-1), and the transcription factor Bcl6. This lineage of CD4 + T cells has been largely defined in the setting of vaccine responses, pathogen infections, and autoimmunity (18) , but its role in allograft rejection and alloantibody responses after transplantation has been largely unexplored (19, 20) .
We and others have previously reported that selective blockade of the CD28 pathway leads to improved allograft survival compared with CTLA4-Ig in preclinical murine and nonhuman primate (NHP) transplant models (21) (22) (23) . Several mechanisms to explain this survival benefit have been put forward. Poirier et al postulated that the survival benefit of selective CD28 blockade is a result of improved CTLA4-dependent, regulatory T cell (Treg)-mediated immune regulation (21, 24) , while we have reported that anti-CD28 treatment with a selective CD28 domain antibody (dAb) mediates CTLA4-dependent upregulation of the 2B4 coinhibitor that leads to improved control of graft-reactive CD8 + T cells (22) . However, the impact of selective CD28 blockade on the Tfh cell-mediated humoral response and DSA production has not been carefully examined in an in vivo preclinical transplant model, and whether selective blockade can differentially affect this arm of the alloimmune response compared with CTLA4-Ig is not known.
In this study, we identified and characterized both T cell receptor (TCR) transgenic and endogenous, polyclonal donor-reactive Tfh cells in our established murine membrane-bound ovalbumin (mOVA) skin transplant model. We observed that selective CD28 blockade resulted in superior inhibition of the Tfh cell response compared with CTLA4-Ig and found that donor-specific Tfh cells differentially upregulated the coinhibitor CTLA4 relative to activated, non-Tfh CD4 + T cells, as well as in response to a mismatched donor graft. Selective CD28 blockade also resulted in better control of GC B cell responses and prevention of de novo DSA formation relative to CTLA4-Ig. These findings support the development of next-generation costimulation blockade in the form of selective CD28 blockers that spare the inhibitory and regulatory functions of CTLA4 as a more potent immunosuppressive strategy to combat DSA in clinical transplantation to improve long-term kidney transplantation outcomes.
Materials and Methods
Mice C57BL/6 mice were obtained from the National Cancer Institute (Frederick, Maryland), and ovalbumin (OVA)-specific TCR transgenic OT-I (25) and OT-II (26) mice purchased from Taconic Farms (Germantown, New York) were bred to Thy1.1 + background from The Jackson Laboratory (Sacramento, California) at Emory University. C57BL/6 mice that constitutively express membrane-bound OVA under the b-actin promoter (mOVA mice) (27) were a gift from M. Jenkins (University of Minnesota). All animals were housed in pathogen-free facilities and maintained in accordance with Emory University Institutional Animal Care and Use Committee guidelines.
T cell adoptive transfers, skin transplantation, and immunosuppression into na€ ıve C57BL/6 mice. At 1-2 days after the adoptive transfers, fullthickness tail and ear skin grafts were transplanted onto the dorsal thorax of recipient mice (29) . Skin graft recipients then received no treatment, human CTLA4-Ig (200 lg; Bristol-Myers Squibb, Princeton, NJ), or anti-CD28 dAb (100 lg; Bristol-Myers Squibb). CTLA4-Ig and anti-CD28 dAbs were administered intraperitoneally on posttransplantation days 0, 2, 4, and 6 and then weekly thereafter until death. Reagent dosing was based on molecular weight, serum half-life, and murine mixed lymphocyte reaction EC 50 (Table 1) .
Flow cytometry
Graft-draining axillary and brachial lymph nodes were processed into single-cell suspensions. Cells were surface stained for CD3, CD4, CD19, CD44, CXCR5, PD-1, ICOS, Thy1.1, IgD, CD95, and GL-7 and pulsed with LIVE/DEAD viability dye (Molecular Probes, Eugene, OR) before fixation. CXCR5 staining was performed by using one-step and three-step (30) techniques. Intracellular staining for Bcl6, CTLA4, and Foxp3 was performed by using the Foxp3 Fixation/Permeabilization Buffer Kit (eBioscience, San Diego, CA). All antibodies were purchased from BioLegend (San Diego, CA) and BD Biosciences. All samples were run on an LSR Fortessa flow cytometer (BD Biosciences) and analyzed by using FlowJo Software (Tree Star, Ashland, OR). CountBright Beads (Invitrogen, Carlsbad, CA) were used to determine absolute cell counts.
ELISA anti-OVA antibody assessment
Flat-bottom 96-well Immulon microtiter plates (VWR) were coated with OVA protein (100 lg/well; Sigma-Aldrich) in 0.05 mol/L carbonate- 
Statistical analysis
The Mann-Whitney U nonparametric t test was performed for analysis of unpaired groups, and the Holms-Sidak method was used for grouped, multiple t test analyses. All analyses were performed by using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA Figure 1A ). Mice were killed 10 days posttransplantation for flow cytometric draining lymph node (DLN) analysis. Adoptively transferred Thy1.1 + OVA-specific CD4 + T cells expanded in response to the mOVA graft but not to the B6 isograft ( Figures 1B,C) . Examination of these OVAspecific, congenically labeled Thy1.1 + OT-II T cells by the canonical Tfh cell phenotypic markers CXCR5 and PD-1 (17) revealed robust expansion of transgenic donor-specific Tfh cells in response to an mOVA skin graft ( Figures 1D,G 
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+ Tfh cells after an mOVA skin graft compared with a syngeneic B6 graft ( Figures 1E-G) .
Further analysis of the TCR transgenic and endogenous donor-specific Tfh cell subsets revealed that a fraction of both express GL7 (Figures 2A,C) , an activation marker that distinguishes less polarized GL7 À Tfh cells from more-polarized GL7 + GC Tfh cells (32) . GL7 + GC Tfh cells expressed the highest levels of CXCR5, PD-1, Bcl6, and ICOS ( Figures 2B,D) , consistent with their reported more-mature differentiation status and enhanced ability to provide B cell help (17) . Thus, transgenic and endogenous, polyclonal donor-specific Tfh cells are detectable and accumulate in response to a skin graft, manifesting the characteristics typical of the multistage differentiation process Tfh cells undergo for GC formation and the provision of B cell help.
Selective CD28 pathway blockade results in superior inhibition of donor-reactive Tfh cells Based on previous work from our group and others showing that selective CD28 blockade leads to improved graft survival and has a differential impact on certain T cell subsets compared with CTLA4-Ig (22, 24) , we sought to test the impact of a selective anti-CD28 dAb on Tfh cells in our murine mOVA skin transplant model. After adoptive transfer of Thy1.1 + OT-I and OT-II T cells, na€ ıve B6 recipient mice were transplanted with mOVA skin grafts and left untreated or were treated with either CTLA4-Ig or the anti-CD28 dAb ( Figure 3A ). All mice were killed 10 days posttransplantation for DLN analysis. Consistent with our prior observation, OVA-specific Thy1.1 + CD4 + T cells were significantly reduced in animals treated with the anti-CD28 dAb compared with CTLA4-Ig (Figures 3B,C). Further examination of the Thy1.1 + compartment for donor-specific Bcl6 + PD-1 high Tfh cells revealed similar differential inhibition between treatment groups ( Figure 3D ). Both the frequency and number of donor-specific Bcl6 + PD-1 high Tfh cells were more greatly inhibited by the selective CD28 dAb compared with CTLA4-Ig ( Figure 3E ). This improved inhibition of TCR transgenic Tfh cell accumulation with the anti-CD28 dAb was also observed within the endogenous, polyclonal Bcl6 + PD-1 high Tfh cell response to the mOVA graft ( Figure 3F ). The accumulation of donor-specific Thy1.1 À Bcl6 + PD-1 high Tfh cells as measured by frequency and number was more significantly inhibited by selective CD28 pathway blockade compared with CTLA4-Ig ( Figure 3G ). Hence, selective blockade of the CD28 pathway leads to improved inhibition of both TCR transgenic and endogenous, polyclonal donor-specific Tfh cell responses to a skin graft.
Donor-specific Tfh cells differentially upregulate CTLA4
The coinhibitory molecule CTLA4 has been recently implicated as a mediator of Tfh cell differentiation and function (33) (34) (35) ; however, its role on Tfh cells in transplantation is unknown. To begin to investigate whether intact CTLA4 on donor-reactive Tfh cells could be a mechanism underlying the improved inhibition of Tfh cells with selective CD28 blockade, we examined the level of expression of CTLA4 on Tfh cells in response to a donor skin graft. Mice were adoptively transferred Thy1.1 + OT-I and OT-II cells, transplanted mOVA skin, and killed 10 days posttransplantation for DLN analysis ( Figure 1A ). We observed that both TCR transgenic and endogenous, polyclonal We next sought to determine whether the increased expression of CTLA4 after a skin graft parallels the expression of Bcl6, CXCR5, and PD-1 by Tfh cells and is commensurate with a more-activated state in response to recognition of donor antigen. Thus, using our same experimental model ( Figure 1A) , we evaluated the expression of CTLA4 on endogenous, CD44 + Thy1.1 À Tfh cells in response to an mOVA skin graft relative to a syngeneic B6 graft ( Figure 5A ). We found that the frequency of CTLA4 + cells and expression levels of CTLA4, Bcl6, and CXCR5 did not change between CD44 + , CXCR5 À PD-1 + non-Tfh CD4 + T cells following either a B6 or an mOVA skin graft ( Figures 5B,C) . The mOVA graft did induce a small increase in PD-1 expression on these nonTfh cells. Conversely, graft-reactive CXCR5 + PD-1 high Tfh cells specifically exhibited a significant increase in the frequency of CTLA4 + cells in the mOVA-but not the B6-grafted mice, and CTLA4, Bcl6, CXCR5, and PD-1 expressions were greatest after the mOVA graft compared with the isograft (Figures 5D,E) . Taken together, these data indicate that the differential expression of CTLA4 on Tfh cells after a donor-mismatched graft parallels Bcl6 and CXCR5 expression and is a result of antigen exposure.
Selective CD28 pathway blockade leads to superior inhibition of donor-elicited GC B cells The principal role of Tfh cells is to provide help to cognate B cells for the formation of GCs to generate mature antibody responses (17) . We analyzed DLNs 10 days after skin grafting for GC B cell accumulation as a measure of the magnitude of the T cell-dependent B cell response and GC reaction. Using the same murine skin transplant model ( Figure 1A) , na€ ıve B6 mice were adoptively transferred OT-I and OT-II T cells, transplanted with syngeneic B6 or mOVA skin grafts, and killed 10 days posttransplantation for DLN analysis. The frequency and number of CD19 + IgD À class-switched B cells were significantly increased after the mOVA skin graft ( Figures 6A,B) . GC B cells were identified as the CD95 + GL7 + fraction of CD19 + IgD À B cells ( Figure 6C ) (36) . Donor-elicited GC B cell frequency and number were significantly increased after an mOVA skin graft compared with the accumulation of nonspecific GC B cells in response to a B6 isograft ( Figure 6D ). GC B cell analysis of mice treated with CTLA4-Ig or anti-CD28 dAb ( Figure 3A) revealed that both agents significantly inhibited donor-elicited GC B cell accumulation compared with untreated mice after an mOVA skin graft ( Figure 6E) ; however, selective CD28 blockade led to significantly greater inhibition of donor-elicited GC B cells compared with CTLA4-Ig (Figure 6F) . Thus, selective CD28 pathway blockade induces better control of not only donor-specific Tfh cell responses but also the cognate, graft-elicited GC B cell response compared with nonselective blockade with CTLA4-Ig. ( Figure 7A ). Serum from mice in all treatment groups was measured via use of an ELISA for anti-OVA IgG levels after transplantation. DSA production was observed in the untreated mOVA-grafted mice, whereas no anti-OVA antibodies were detected in the isograft recipients ( Figure 7B ). CTLA4-Ig treated mice exhibited delayed but significant DSA formation relative to untreated and syngeneic controls, and anti-CD28 dAb- + cells and CTLA4, CXCR5, and PD-1 expression (n = 5). Summary data represent mean (SE) and are representative of four independent experiments with a total of 15-20 mice. *p < 0.05, **p < 0.01. treated mice experienced no detectable DSA formation. Serum DSA titers 21 days posttransplantation at the peak of the anti-OVA IgG response corroborated our finding that the selective CD28 blocker provides superior inhibition of DSAs compared with CTLA4-Ig ( Figure 7C ). This differential inhibition of DSA was sustained beyond 56 days posttransplantation ( Figure 7D ). Accordingly, better prevention of DSA formation by the anti-CD28 dAb compared with CTLA4-Ig is consistent with the overall improved inhibition of Tfh-mediated responses observed with selective CD28 pathway blockade after transplantation.
Discussion
As knowledge of Tfh cell biology continues to rapidly grow, the role of this subset in mediating T celldependent antibody responses (TDARs) becomes increasingly relevant to the field of transplantation (19, 20) . Anti-HLA DSA arising from alloantigen-specific cognate Tfh-GC B cell interactions for the production of high-affinity alloantibodies, and alloreactive memory B cells and longlived plasma cells via the GC reaction, are now a wellrecognized immunologic barrier to improved long-term outcomes in kidney transplantation as mediators of antibody mediated rejection (AMR) (1, 5, 6, 8) . Current available therapies aimed at humoral allosensitization target B cells (e.g. rituximab), plasma cells (e.g. bortezomib), or DSAs (e.g. plasmapheresis) after alloantibodies have developed with limited efficacy (4,9,37,38), rendering current efforts "too little, too late." Shifting therapeutic focus to using T cell-directed therapies against the initiation of the antibody response by targeting Tfh cells may prove to be the most efficacious and long-lasting method of addressing the clinical problem of alloantibodies. Moreover, therapeutic strategies like costimulation blockade of the CD28 or CD40 pathway that are mechanistically appealing means of targeting Tfh cells have been translated and are clinically available (e.g. CTLA4-Ig) (10) or are in the development pipeline (e.g. anti-CD28 dAb, anti-CD40 mAbs) (39) for potential translation to combat DSA.
Several transplantation studies to date have reported on the favorable immunosuppressive impact of costimulatory blockade on the Tfh-GC axis responsible for antidonor antibody formation. In a mouse model of chronic graft-versus-host disease (cGVHD) caused in part by alloantibody secretion, increased Tfh and GC B cells were required for cGVHD, and interleukin (IL)-21, ICOS, and CD40 blockade all hindered GC formation and alloantibody-mediated cGVHD (40) . Similarly, in an NHP kidney transplant model of AMR, costimulation blockade with belatacept or an anti-CD40 mAb prevented de novo DSAs and was associated with reduced GC Tfh cells and GC reactivity as indicated by interleukin-21 production (41). Moreover, CTLA4-Ig has been effective at controlling de novo DSA responses in mice (42) , and delayed use of anti-CD154 and/or CTLA4-Ig has been shown to dissolve nascent GCs, halt further development of alloantibody responses, established allo-B cell and memory B cell responses, and inhibit ongoing B cell responses in murine cardiac allograft models (43) (44) (45) . Overall, there is growing evidence that pursuing costimulation blockade strategies is a viable and promising method to combat humoral alloimmunity and the DSA burden in transplantation. CD28-deficient mice exhibit significantly impaired immunoglobulin concentrations and class switching and do not undergo the proliferative expansion necessary for GC formation (46, 47) . As a result, CD28 is required for TDARs and the CD28 deficient phenotype is presumed to be due to a lack of Tfh cells. In contrast, CTLA4-deficient mice exhibit lethal lymphoproliferative disease characterized by hypergammaglobulinemia (48, 49) , and more recent data from the Sharpe and Sakaguchi laboratories have shown that CTLA4 critically controls multiple aspects of the GC reaction (33, 35) . In these studies, deletion of CTLA4 on Tfh cells led to enhanced B cell class-switch recombination in vitro and reduction of CTLA4 on T regulatory and T follicular regulatory cells led to augmented humoral responses and defective suppression of GC development. Therefore, existing data on the influence of CD28 costimulation and CTLA4 coinhibition on TDARs provide strong rationale for the use of selective CD28 blockade to tilt the net balance of stimulatory and inhibitory signaling in favor of improved control of Tfh-mediated DSA production.
As previously mentioned, Tregs and CD8 + T cells have both been shown to exhibit differential responses to selective CD28 blockade versus CTLA4-Ig as possible mechanisms responsible for the improved immunosuppressive effect and graft prolongation of selective CD28 blockade (22, 24 ). Ville et al tested an anti-CD28 antibody in an NHP model of kidney transplantation and showed less incidence of acute rejection compared with belatacept (23) . In exploring the mechanisms responsible for this observation, the authors identified an insignificant trend of higher Treg frequencies in anti-CD28-treated animals and increased levels of the Tfh-associated cytokine IL-21 in belatacept-treated animals. The anti-CD28 antibody also resulted in better in vitro control of Tfh cell proliferation and improved control of secondary antibody responses to KLH antigen immunization in mice. These data circumstantially suggest that Tfh cells may in part mediate the improved results that were observed with selective CD28 blockade. To directly determine the impact of selective CD28 blockade on the Tfh cell response and development of DSA, we used an in vivo preclinical transplant model in this study.
We show that selective CD28 blockade in a murine transplant model leads to greater inhibition of donor-reactive Tfh cells, GC B cells, and antidonor antibody responses relative to CTLA4-Ig. The use of TCR transgenic systems to facilitate examination of antigen-specific cells has met skepticism as a surrogate for natural, unfettered endogenous alloimmune responses. Model antigen T cell transgenic systems have been criticized to be nonrepresentative of endogenous, polyclonal responses and to alter aspects of endogenous alloimmunity (50) . Here, we utilized an mOVA skin graft model to afford us the ability to examine the true donor-specific Tfh cell response by tracking OVA-specific TCR transgenic T cells, as well as the nontransgenic, OVA-reactive endogenous Tfh cell response. In this system, both transgenic and endogenous Tfh cells manifested the same phenotypic and differentiation characteristics in response to a donor skin graft (Figures 1,2,4 ) and were equally inhibited by CD28 pathway blockade with either CTLA4-Ig or anti-CD28 dAbs ( Figure 3 ). While we expect the introduction of TCR transgenic T cells to affect the immune response by altering donor-reactive precursor frequency and the balance of competition for antigen between transgenic and endogenous cells, our results indicate that both populations of donor-reactive Tfh cells manifest characteristics consistent with the literature and respond equally to the immunosuppressive reagents tested here.
CTLA4-Ig is known to be less effective in more immunologically stringent mouse and NHP models (29, 51, 52) and has been associated with higher rates of acute rejection after kidney transplantation in humans (53) . The exact mechanisms mediating this CTLA4-Ig resistance have not been entirely elucidated, but ironically the mechanism of action of CTLA4-Ig may underlie this reduced efficacy (54) . Because CTLA4-Ig binds to CD80/86 on antigenpresenting cells and blocks their engagement with both CD28 and CTLA4, it is likely that blocking CTLA4 may detract from the overall goal of attenuating alloreactive T cell responses, in that CTLA4 is inhibitory and activates regulatory T cells to abrogate immune responses (48, 49, 55) . In support of this hypothesis, we previously demonstrated that improved inhibition of donor-reactive CD8 + T cells with selective CD28 blockade is CTLA4 dependent (22) . Our current observation that CTLA4 is differentially upregulated on donor-reactive Tfh cells in response to a skin graft (Figures 4,5 ) strongly suggests that CTLA4 also plays an important inhibitory or regulatory role in Tfh cell-mediated DSA responses and that the superior anti-CD28 dAb-mediated inhibition of the donorreactive Tfh cell response may be CTLA4 dependent. We postulate that blockade of CTLA-mediated inhibition of Tfh cells underlies the inability of CTLA4-Ig to completely prevent DSA formation in both humans (10,13) (I. R. Badell, unpublished data) and our experimental model. However, whether the observed impact of CD28-specific antagonism on the Tfh cell response and DSA is CTLA4 dependent remains to be determined and is currently under investigation in our laboratory.
While we found that selective CD28 blockade preferentially inhibited the donor-reactive Tfh cell response relative to CTLA4-Ig in this study, the anti-CD28 dAbs were systemically delivered and free to interact with CD28 on a variety of immune cell types with a multitude of antigen specificities. Considering the ubiquitous roles of CD28 and CTLA4, it is possible that the observed superior antihumoral effect of the anti-CD28 dAb is not exclusive to Tfh cells. In fact, the early extrafollicular antibody response is known to be GC independent (56, 57) and has been shown to also depend on CD4 + T cells (58, 59 ).
Thus, improved inhibition of DSA with selective CD28 blockade may not be solely secondary to Tfh-dependent antibody production immediately after transplantation. Moreover, because CD28 costimulation blockade has been clinically associated with concerns regarding virusspecific immunity (14, 60) , the impact of more-potent selective CD28 blockade on pathogen-specific T cells warrants close attention. Overall, the direct effect of the anti-CD28 dAb on protective immune responses and whether our findings directly result from an intrinsic effect on the CD4 + Tfh cell lineage remain to be studied.
In summary, this study introduces Tfh cells and the Tfhmediated response as additional components of the antidonor adaptive immune response that experience superior inhibition with the use of selective CD28 costimulation blockade compared with CTLA4-Ig in transplantation. Our data highlight that targeting CD28 costimulation while leaving the coinhibitor CTLA4 free to engage the B7 ligands results in better inhibition of Tfh cells, GC B cells, and DSAs in response to a donor skin graft and that the expression of CTLA4 is differentially elevated on the Tfh cell lineage, suggesting a CTLA4-dependent, Tfh cell intrinsic mechanism of improved inhibition with selective CD28 blockade that warrants further study. These findings, along with continued work clarifying the net cell intrinsic influence of costimulatory and coinhibitory signaling on Tfh cell differentiation and function, and Tfh-dependent antibody production promises to guide therapeutic strategies aimed at controlling deleterious anti-HLA antibodies and improving long-term outcomes in kidney transplantation.
